WP Advisors LLC Raises Holdings in Pfizer Inc. $PFE

WP Advisors LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 2.4% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 528,805 shares of the biopharmaceutical company’s stock after acquiring an additional 12,259 shares during the period. Pfizer accounts for about 3.5% of WP Advisors LLC’s investment portfolio, making the stock its 8th biggest holding. WP Advisors LLC’s holdings in Pfizer were worth $12,818,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. GKV Capital Management Co. Inc. bought a new position in Pfizer during the 1st quarter worth $27,000. Curio Wealth LLC lifted its stake in Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares during the last quarter. Bayforest Capital Ltd acquired a new position in shares of Pfizer during the first quarter valued at $28,000. Harbor Asset Planning Inc. bought a new position in shares of Pfizer during the second quarter worth about $29,000. Finally, WPG Advisers LLC acquired a new stake in shares of Pfizer in the 1st quarter worth about $35,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of NYSE PFE opened at $25.80 on Friday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The firm has a market cap of $146.66 billion, a P/E ratio of 13.72, a PEG ratio of 0.81 and a beta of 0.54. The stock has a fifty day moving average price of $24.79 and a two-hundred day moving average price of $24.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on PFE. Citigroup boosted their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. UBS Group reaffirmed a “neutral” rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Scotiabank initiated coverage on Pfizer in a research report on Thursday. They issued a “sector outperform” rating and a $30.00 target price on the stock. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $26.00 price target on shares of Pfizer in a research report on Wednesday, November 5th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.28.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.